GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Excelsior Biopharma Inc (ROCO:6496) » Definitions » Debt-to-Equity

Excelsior Biopharma (ROCO:6496) Debt-to-Equity : 0.34 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Excelsior Biopharma Debt-to-Equity?

Excelsior Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$77.2 Mil. Excelsior Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$300.3 Mil. Excelsior Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$1,104.5 Mil. Excelsior Biopharma's debt to equity for the quarter that ended in Dec. 2023 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Excelsior Biopharma's Debt-to-Equity or its related term are showing as below:

ROCO:6496' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.09   Max: 0.34
Current: 0.34

During the past 12 years, the highest Debt-to-Equity Ratio of Excelsior Biopharma was 0.34. The lowest was 0.01. And the median was 0.09.

ROCO:6496's Debt-to-Equity is ranked worse than
53.75% of 854 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs ROCO:6496: 0.34

Excelsior Biopharma Debt-to-Equity Historical Data

The historical data trend for Excelsior Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Excelsior Biopharma Debt-to-Equity Chart

Excelsior Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.31 0.32 0.31 0.34

Excelsior Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.31 0.35 0.35 0.34

Competitive Comparison of Excelsior Biopharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Excelsior Biopharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Excelsior Biopharma's Debt-to-Equity falls into.



Excelsior Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Excelsior Biopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Excelsior Biopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Excelsior Biopharma  (ROCO:6496) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Excelsior Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Excelsior Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Excelsior Biopharma (ROCO:6496) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 14th Floor-6, Nangang District, Taipei, TWN, 11503
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, research of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.

Excelsior Biopharma (ROCO:6496) Headlines

No Headlines